Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human, Randomized, Observer-blind, Parallel Design, Controlled, Dose Level and Schedule-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying mRNA Pandemic Influenza Vaccine (ARCT-2304) When Administered to Healthy Adults

NCT06602531 is registered in ClinicalTrials.gov with Arcturus Therapeutics, Inc. as lead sponsor.

NCT NCT06602531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06602531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human, Randomized, Observer-blind, Parallel Design, Controlled, Dose Level and Schedule-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying mRNA Pandemic Influenza Vaccine (ARCT-2304) When Administered to Healthy Adults
Lead sponsor
Arcturus Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
December 10, 2024
Completion date
December 5, 2025
Enrollment
212 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human